An Exploratory Biomarker Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Biomarker evidence of MDM2 and p53 pathway alterations (histologic, molecular and imaging analyses)
from baseline to week 12
No
Clinical Trials
Study Director
Hoffmann-La Roche
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
NP22890
NCT01143740
June 2010
March 2011
Name | Location |
---|